Bluejay Diagnostics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Bluejay Diagnostics implemented a 1-for-4 reverse stock split effective November 3, 2026, reducing outstanding common shares from ~4.47M to ~1.12M shares. No fractional shares will be issued; holders receive cash in lieu. All equity awards, warrants, and the authorized share count (now 250M common, 5M preferred of 255M total) were adjusted proportionally. No change to par value ($0.0001/share); stockholders' percentage ownership unchanged except for fractional-share rounding.
Why this rating
Reverse split is routine capital structure housekeeping, common for low-priced stocks, does not alter ownership or business operations. No material financial impact relative to $2.6M market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.